The study of p53 and CA19-9 prognostic molecular markers in colorectal carcinomas

Romanian Journal of Morphology and Embryology

Volumn 51, Issue 3, 2010, Pages 473-481

  Afrem, Georgeta ^a   Crǎiţoiu, Ştefania ^a   Margaritescu C ^a   Mogoanta S S ^b  

^a Department of Medical Expertise and Recovery of Work Capacity ^*

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

Author keywords

CA19 9 antibody; Molecular markers in CCR; p53 antibody

Indexed keywords

CA 19-9 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; COLLOID CARCINOMA; COLORECTAL TUMOR; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CA-19-9 ANTIGEN; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77956989463     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ, Cancer statistics, 2009, CA Cancer J Clin, 2009, 59(4):225-249.
2. Center MM, Jemal A, Ward E, International trends in colorectal cancer incidence rates, Cancer Epidemiol Biomarkers Prev, 2009, 18(6):1688-1694.
3. Jesus EC, Matos D, Artigiani R, Waitzberg AF, Goldenberg A, Saad SS, Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins, Acta Cir Bras, 2005, 20(6):422-427.
4. Longley DB, Mcdermott U, Johnston PG, Clinical significance of prognostic and predictive markers in colorectal cancer, Pharmacogenomics J, 2002, 2(4):209-216. Georgeta Afrem et al. 480
5. Hamilton SR, Vogelstein B, Kudo S, Riboli E, Nakamura S, Hainaut P, Rubio CA, Sobin LH, Fogt F, Winawer SJ, Goldar DE, Jass JR, Tumours of the colon and rectum.In: Hamilton SR, Aaltonen LA (eds), World Health Organization Classification of Tumours. Pathology and genetics of tumours of the digestive system, IARC Press, Lyon, 2000, 103-143.
6. Potter JD, Colorectal cancer: molecules and populations, J Natl Cancer Inst, 1999, 91(11):916-932.
7. Siegel RL, Jemal A, Ward EM, Increase in incidence of colorectal cancer among young men and women in the United States, Cancer Epidemiol Biomarkers Prev, 2009, 18(6):1695-1698.
8. Gupta AK, Melton LJ 3RD, Petersen GM, Timmons LJ, Vege SS, Harmsen WS, Diehl NN, Zinsmeister AR, Ahlquist DA, Changing trends in the incidence, stage, survival and screen-detection of colorectal cancer: a population- based study, Clin Gastroenterol Hepatol, 2005, 3(2):150-158.
9. Rabeneck L, Davila JA, El-Serag HB, Is there a true "shift" to the right colon in the incidence of colorectal cancer?, Am J Gastroenterol, 2003, 98(6):1400-1409.
10. Salminen E, Palmu S, Vahlberg T, Roberts PJ, Söderström KO, Increased proliferation activity measured by immunoreactive Ki67 is associated with survival improvement in rectal/recto sigmoid cancer, World J Gastroenterol, 2005, 11(21):3245-3249.
11. Pollheimer MJ, Kornprat P, Pollheimer VS, Lindtner RA, Schlemmer A, Rehak P, Langner C, Clinical significance of pT sub-classification in surgical pathology of colorectal cancer, Int J Colorectal Dis, 2010, 25(2):187-196.
12. Tornillo L, Lugli A, Zlobec I, Willi N, Galtz K, Lehmann F, Spichtin HP, Maurer R, Stoios D, Sauter G, Terracciano L, Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach, Am J Clin Pathol, 2007, 127(1):114-123.
13. Tsai HL, Cheng KI, Lu CY, Kuo CH, Ma CJ, Wu JY, Chai CY, Hsieh JS, Wang JY, Prognostic significance of depth of invasion, vascular invasion and numbers of lymph node retrievals in combination for patients with stage II colorectal cancer undergoing radical resection, J Surg Oncol, 2008, 97(5):383-387.
14. Liu W, Nie SF, Chen JG, Huang T, He JJ, Liu C, Study on the prognostic factors of colorectal cancer and on suggested model for prediction, Zhonghua Liu Xing Bing Xue Za Zhi, 2007, 28(7):700-703.
15. Hamilton SR, Rubio, CA, Vogelstein B, Sobin LH, Kudo S, Fogt F, Riboli E Winawer SJ, Nakamura S, Goldgar DE, Hainaut P, Jass R, Carcinoma of the colon and rectum. In: Hamilton SR, Aaltonen LA (eds), World Health Organization Classification of Tumors. Pathology and genetics of tumors of digestive system, IARC Press, Lyon, 2000, 105-119.
16. Kanemitsu Y, Kato T, Hirai T, Yasui K, Morimoto T, Shimizu Y, Kodera Y, Yamamura Y, Survival after curative resection for mucinous adenocarcinoma of the colorectum, Dis Colon Rectum, 2003, 46(2):160-167.
17. Wu X, Chen VW, Martin J, Roffers S, Groves FD, Correa CN, Hamilton-Byrd E, Jemal A; Comparative Analysis Of Incidence Rates Subcommittee, Data Evaluation And Publication Committee, North American Association Of Central Cancer Registries, Subsitespecific colorectal cancer incidence rates and stage distributions among Asians and Pacific Islanders in the United States, 1995 to 1999, Cancer Epidemiol Biomarkers Prev, 2004, 13(7):1215-1222.
18. Papadopoulos VN, Michalopoulos A, Netta S, Basdanis G, Paramythiotis D, Zatagias A, Berovalis P, Harlaftis N, Prognostic significance of mucinous component in colorectal carcinoma, Tech Coloproctol, 2004, 8 Suppl 1:s123-s125.
19. Anwar S, Frayling IM, Scott NA, Carlson GL, Systematic review of genetic influences on the prognosis of colorectal cancer, Br J Surg, 2004, 91(10):1275-1291.
20. Grem JL, Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer, Semin Oncol, 2005, 32(1):120-127.
21. Mcleod HL, Church RD, Molecular predictors of prognosis and response to therapy in colorectal cancer, Cancer Chemother Biol Response Modif, 2003, 21:791-801.
22. Munro AJ, Lain S, Lane DP, P53 abnormalities and outcomes in colorectal cancer: a systematic review, Br J Cancer, 2005, 92(3):434-444.
23. Westra JL, Plukker JT, Buys CH, Hofstra RM, Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers, Clin Colorectal Cancer, 2004, 4(4):252-259.
24. Bara J, Zabaleta EH, Mollicone R, Nap M, Bunin P, Distribution of GICA in normal gastrointestinal and endocervical mucosae and in mucinous ovarian cysts using antibody NS 19-9, Am J Clin Pathol, 1986, 85(2):152-159.
25. Arends JW, Verstynen C, Bosman FT, Hilgers J, Steplewski Z, Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study, Hybridoma, 1983, 2(2):219-229.
26. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H, Gastrointestinal cancer-associated antigen in immunoperoxidase assay, Cancer Res, 1982, 42(11):4820-4823.
27. Gong E, Hirohashi S, Shimosato Y, Watanabe M, Ino Y, Teshima S, Kodaira S, Expression of carbohydrate antigen 19-9 and stage-specific embryonic antigen 1 in nontumorous and tumorous epithelia of the human colon and rectum, J Natl Cancer Inst, 1985, 75(3):447-454.
28. Yuan M, Itzkowitz SH, Boland CR, Kim YD, Tomita JT, Palekar A, Bennington JL, Trump BF, Kim YS, Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry, Cancer Res, 1986, 46(9):4841-4847.
29. Afdhal NH, Long A, Tobbia I, Cullen A, O'donoghue DP, Immunohistochemical Cal19-9 in primary colonic polyps and polyps synchronous with colorectal cancer, Gut, 1987, 28(5):594-600.
30. Olding LB, Åhren C, Svalander C, Thurin J, Karlsson KA, Koprowski H, Gastrointestinal carcinoma-associated antigen detected by a monoclonal antibody in dysplasia and adenocarcinoma associated with chronic ulcerative colitis, Int J Cancer, 1985, 36(2):131-136.
31. Itzkowitz SH, Yuan M, Fukushi Y, Lee H, Shi ZR, Zurawski V Jr, Hakomori S, Kim YS, Immunohistochemical comparison of Lea, monosialosyl Lea (CA 19-9), and disialosyl Lea antigens in human colorectal and pancreatic tissues, Cancer Res, 1988, 48(13):3834-3842.
32. Shimono R, Mori M, Akazawa K, Adachi Y, Sgimachi K, Immunohistochemical expression of carbohydrate antigen 19-9 in colorectal carcinoma, Am J Gastroenterol, 1994, 89(1):101-105.
33. Morales-Gutiérrez C, Vegh I, Colina F, Gómez-Cámara A, Ignacio Landa J, Ballesteros D, Carreira PE, Enríquezde-Salamanca R, Survival of patients with colorectal carcinoma: possible prognostic value of tissular carbohydrate antigen 19.9 determination, Cancer, 1999, 86(9):1675-1681.
34. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Aglund C, CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers, Anticancer Res, 2002, 22(4):2311-2316.
35. LOCKER GY, HAMILTON S, HARRIS J, JESSUP JM, KEMENY N, MACDONALD JS, SOMERFIELD MR, HAYES DF, BAST RC JR; ASCO, ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer, J Clin Oncol, 2006, 24(33):5313-5327.
36. SAFI F, KUHNS T, BEGER HG, Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer, Int J Biol Markers, 1995, 10(2):100-106.
37. Uygur-Bayramicli O, Dabak R, Orbay E, Dolapcioglu C, Sargin M, Kilicoglu G, Guleryuzlu Y, Mayadagli A, Type 2 diabetes mellitus and CA 19-9 levels, World J Gastroenterol, 2007, 13(40):5357-5359.
38. Diez M, Cerdán FJ, Pollán M, Maestro ML, Ortega MD, Martínez S, Moreno G, Balibrea JL, Prognostic significance of preoperative serum CA 19.9 assay in patients with colorectal carcinoma, Anticancer Res, 1994, 14(6B):2819-2825.
39. FORONES NM, TANAKA M, CEA and CA 19-9 as prognostic indexes in colorectal cancer, Hepatogastroenterology, 1999, 46(26):905-908.
40. KATOH H, YAMASHITA K, KOKUBA Y, SATOH T, OZAWA H, HATATE K, IHARA A, NAKAMURA T, ONOSATO W, WATANABE M, Surgical resection of stage IV colorectal cancer and prognosis, World J Surg, 2008, 32(6):1130-1137.
41. LISKA V, HOLUBEC L JR, TRESKA V, SKALICKY T, SUTNAR A, KORMUNDA S, PESTA M, FINEK J, ROUSAROVA M, TOPOLCAN O, Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases, Anticancer Res, 2007, 27(4C):2861-2864.
42. MINEO TC, AMBROGI V, TONINI G, BOLLERO P, ROSELLI M, MINEO D, NOFRONI I, Longterm results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma, J Am Coll Surg, 2003, 197(3):386-391.
43. NAKAGOE T, SAWAI T, TSUJI T, JIBIKI MA, NANASHIMA A, YAMAGUCHI H, YASUTAKE T, AYABE H, ARISAWA K, Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients, Hepatogastroenterology, 2003, 50(51):696-699.
44. NAKAYAMA T, WATANABE M, TERAMOTO T, KITAJIMA M, CA19-9 as predictor of recurrence in patients with colorectal cancer, J Surg Oncol, 1997, 66(4):238-243.
45. SATO T, NISHIMURA G, NONOMURA A, MIWA K, MIYAZAKI I, Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer, Hepatogastroenterology, 1999, 46(26):914-919.
46. REITER W, STIEBER P, REUTER C, NAGEL D, LAU-WERNER U, LAMERZ R, Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer, Anticancer Res, 2000, 20(6D):5195-5198.
47. WANG WS, LIN JK, CHIOU TJ, LIU JH, FAN FS, YEN CC, LIN TC, JIANG JK, YANG SH, WANG HS, CHEN PM, CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer, Hepatogastroenterology, 2002, 49(43):160-164.
48. GASSER M, GERSTLAUER C, GRIMM M, BUETER M, LEBEDEVA T, LUTZ J, MAEDER U, RIBAS C, RIBAS C, NICHIPORUK E, THALHEIMER A, HEEMANN U, THIEDE A, MEYER D, WAAGA-GASSER AM, Comparative analysis of predictive biomarkers for therapeutical strategies in colorectal cancer, Ann Surg Oncol, 2007, 14(4):1272-1284.
49. MORITA S, NOMURA T, FUKUSHIMA Y, MORIMOTO T, HIRAOKA N, SHIBATA N, Does serum CA19-9 play a practical role in the management of patients with colorectal cancer?, Dis Colon Rectum, 2004, 47(2):227-232.
50. TAKEDA A, SHIMADA H, NAKAJIMA K, YOSHIMURA S, SUZUKI T, ASANO T, OCHIAI T, ISONO K, Serum p53 antibody as a useful marker for monitoring of treatment of superficial colorectal adenocarcinoma after endoscopic resection, Int J Clin Oncol, 2001, 6(1):45-49.
51. THOMAS WM, ROBERTSON JF, PRICE MR, HARDCASTLE JD, Failure of CA19-9 to detect asymptomatic colorectal carcinoma, Brit J Cancer, 1991, 63(6):975-976.
52. WEBB A, SCOTT-MACKIE P, CUNNINGHAM D, NORMAN A, ANDREYEV J, O'BRIEN M, BENSTED J, The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer, Ann Oncol, 1995, 6(6):581-587.
53. DESCH CE, BENSON AB 3RD, SOMERFIELD MR, FLYNN PJ, KRAUSE C, LOPRINZI CL, MINSKY BD, PFISTER DG, VIRGO KS, PETRELLI NJ; American Society Of Clinical Oncology, Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline, J Clin Oncol, 2005, 23(33):8512-8519.
54. FUCINI C, TOMMASI SM, ROSI S, MALATANTIS G, CARDONA G, PANICHI S, BETTINI U, Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca 19-9 analysis and second-look surgery, Dis Colon Rectum, 1987, 30(4):273-277.